{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:19:34Z","timestamp":1783408774866,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10072-026-09196-w","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:11:24Z","timestamp":1782285084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic delay and onset-anchored clinical milestones in progressive supranuclear palsy: a japanese single-center retrospective cohort study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7040-3273","authenticated-orcid":false,"given":"Kazuhiro","family":"Horiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaede","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumire","family":"Nunomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"7","key":"9196_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1212\/WNL.36.7.1005","volume":"36","author":"ER Maher","year":"1986","unstructured":"Maher ER, Lees AJ (1986) The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36(7):1005\u20131008. https:\/\/doi.org\/10.1212\/WNL.36.7.1005","journal-title":"Neurology"},{"key":"9196_CR2","doi-asserted-by":"crossref","unstructured":"Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615\u2013620. doi:10.1136\/jnnp.60.6.615.","DOI":"10.1136\/jnnp.60.6.615"},{"issue":"6","key":"9196_CR3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1212\/01.WNL.0000052991.70149.68","volume":"60","author":"U Nath","year":"2003","unstructured":"Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ (2003) Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 60(6):910\u2013916. https:\/\/doi.org\/10.1212\/01.WNL.0000052991.70149.68","journal-title":"Neurology"},{"key":"9196_CR4","doi-asserted-by":"crossref","unstructured":"Tomita S, Oeda T, Umemura A, et al. Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study. PLoS One. 2015;10(8):e0135823. doi:10.1371\/journal.pone.0135823.","DOI":"10.1371\/journal.pone.0135823"},{"issue":"10","key":"9196_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mds.20149","volume":"19","author":"M Kawashima","year":"2004","unstructured":"Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K (2004) Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 19(10):1239\u20131240. https:\/\/doi.org\/10.1002\/mds.20149","journal-title":"Mov Disord"},{"issue":"12","key":"9196_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.557","volume":"6","author":"H Takigawa","year":"2016","unstructured":"Takigawa H, Kitayama M, Wada-Isoe K, Kowa H, Nakashima K (2016) Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav 6(12):e00557. https:\/\/doi.org\/10.1002\/brb3.557","journal-title":"Brain Behav"},{"issue":"8","key":"9196_CR7","first-page":"565","volume":"45","author":"I Aiba","year":"2005","unstructured":"Aiba I, Saito Y, Tamakoshi A, Matsuoka Y (2005) [Prognosis of patients with progressive supranuclear palsy]. Rinsho Shinkeigaku 45(8):565\u2013570","journal-title":"Rinsho Shinkeigaku"},{"key":"9196_CR8","doi-asserted-by":"crossref","unstructured":"Takigawa H, Hanajima R, Aiba I, et al. Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis. Clin Park Relat Disord. 2024;11:100279. doi:10.1016\/j.prdoa.2024.100279.","DOI":"10.1016\/j.prdoa.2024.100279"},{"key":"9196_CR9","doi-asserted-by":"publisher","unstructured":"O\u2019Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362\u20131372.\u00a0https:\/\/doi.org\/10.1093\/brain\/awn065.","DOI":"10.1093\/brain\/awn065"},{"issue":"8","key":"9196_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00415-014-7384-x","volume":"261","author":"M Jecmenica-Lukic","year":"2014","unstructured":"Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261(8):1575\u20131583. https:\/\/doi.org\/10.1007\/s00415-014-7384-x","journal-title":"J Neurol"},{"key":"9196_CR11","doi-asserted-by":"publisher","unstructured":"Guasp M, Molina-Porcel L, Painous C, et al. Association of PSP phenotypes with survival: A brain-bank study. Parkinsonism Relat Disord. 2021;84:77\u201381.\u00a0https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.015.","DOI":"10.1016\/j.parkreldis.2021.01.015"},{"issue":"2","key":"9196_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00415-015-7990-2","volume":"263","author":"JE Arena","year":"2016","unstructured":"Arena JE, Weigand SD, Whitwell JL et al (2016) Progressive supranuclear palsy: progression and survival. J Neurol 263(2):380\u2013389. https:\/\/doi.org\/10.1007\/s00415-015-7990-2","journal-title":"J Neurol"},{"key":"9196_CR13","doi-asserted-by":"publisher","unstructured":"\u00a0Cosseddu M, Benussi A, Gazzina S, et al. Natural history and predictors of survival in progressive supranuclear palsy. J Neurol Sci. 2017;382:105\u2013107.https:\/\/doi.org\/10.1016\/j.jns.2017.09.043.","DOI":"10.1016\/j.jns.2017.09.043"},{"key":"9196_CR14","doi-asserted-by":"publisher","unstructured":"Alster P, Otto-Slusarczyk D, Szlufik S, et al. The significance of glial cell line-derived neurotrophic factor analysis in progressive supranuclear palsy. Sci Rep. 2024;14(1):2805.\u00a0https:\/\/doi.org\/10.1038\/s41598-024-53355-y.","DOI":"10.1038\/s41598-024-53355-y"},{"key":"9196_CR15","doi-asserted-by":"publisher","unstructured":"Madetko-Alster N, Otto-Slusarczyk DE, Wiercinska-Drapalo A, et al. Clinical phenotypes of progressive supranuclear palsy-the differences in interleukin patterns. Int J Mol Sci. 2023;24(20):15135.\u00a0https:\/\/doi.org\/10.3390\/ijms242015135.","DOI":"10.3390\/ijms242015135"},{"issue":"6","key":"9196_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3552","volume":"14","author":"P Alster","year":"2024","unstructured":"Alster P, Otto-Slusarczyk D, Wiercinska-Drapalo A, Struga M, Madetko-Alster N (2024) The potential significance of hepcidin evaluation in progressive supranuclear palsy. Brain Behav 14(6):e3552. https:\/\/doi.org\/10.1002\/brb3.3552","journal-title":"Brain Behav"},{"key":"9196_CR17","doi-asserted-by":"publisher","unstructured":"Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Mov Disord. 2017;32(6):853\u2013864.\u00a0https:\/\/doi.org\/10.1002\/mds.26987.","DOI":"10.1002\/mds.26987"},{"issue":"12","key":"9196_CR18","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/mds.28263","volume":"35","author":"MJ Grimm","year":"2020","unstructured":"Grimm MJ, Respondek G, Stamelou M et al (2020) Clinical conditions \u201csuggestive of progressive supranuclear palsy\u201d-diagnostic performance. Mov Disord 35(12):2301\u20132313. https:\/\/doi.org\/10.1002\/mds.28263","journal-title":"Mov Disord"},{"issue":"7","key":"9196_CR19","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1007\/s00415-023-11629-x","volume":"270","author":"DMA Swallow","year":"2023","unstructured":"Swallow DMA, Counsell CE (2023) The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson\u2019s disease (PD). J Neurol 270(7):3464\u20133474. https:\/\/doi.org\/10.1007\/s00415-023-11629-x","journal-title":"J Neurol"},{"issue":"11","key":"9196_CR20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.parkreldis.2013.06.014","volume":"19","author":"C dell\u2019Aquila","year":"2013","unstructured":"dell\u2019Aquila C, Zoccolella S, Cardinali V et al (2013) Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord 19(11):980\u2013985. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.06.014","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"9196_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.12809\/hkmj198101","volume":"25","author":"YF Shea","year":"2019","unstructured":"Shea YF, Shum ACK, Lee SC et al (2019) Natural clinical course of progressive supranuclear palsy in Chinese patients in Hong Kong. Hong Kong Med J 25(6):444\u2013452. https:\/\/doi.org\/10.12809\/hkmj198101","journal-title":"Hong Kong Med J"},{"issue":"12","key":"9196_CR22","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/01.WNL.0000165960.04422.D0","volume":"64","author":"H Oba","year":"2005","unstructured":"Oba H, Yagishita A, Terada H et al (2005) New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 64(12):2050\u20132055. https:\/\/doi.org\/10.1212\/01.WNL.0000165960.04422.D0","journal-title":"Neurology"},{"issue":"4","key":"9196_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492\u2013499. https:\/\/doi.org\/10.1093\/aje\/kwm324","journal-title":"Am J Epidemiol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09196-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:00:57Z","timestamp":1783407657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09196-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9196"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09196-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was reviewed and approved by the Institutional Review Board of Hakodate Municipal Hospital (Approval No. 2025\u2009\u2212\u2009350).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for written informed consent was waived by the Institutional Review Board because of the retrospective design and use of routinely collected clinical data. Information about the study was disclosed through an opt-out procedure approved by the Institutional Review Board, and patients were given the opportunity to decline participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This manuscript contains no identifiable individual patient data or patient images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"During preparation of this work, the authors used ChatGPT (OpenAI) to improve English language expression, assist manuscript structuring, and support Python script generation. All outputs were reviewed and edited by the authors, who take full responsibility for the content of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies"}},{"value":"The authors declare no relevant financial or non-financial competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"585"}}